ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 83 filers reported holding ONCOMED PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is 1.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $8,876,000 | +19.5% | 963,700 | 0.0% | 0.01% | +25.0% |
Q4 2016 | $7,430,000 | -34.6% | 963,700 | -3.0% | 0.00% | -33.3% |
Q3 2016 | $11,360,000 | +214.0% | 993,900 | +238.2% | 0.01% | +200.0% |
Q2 2016 | $3,618,000 | +21.8% | 293,900 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $2,971,000 | -55.2% | 293,900 | 0.0% | 0.00% | -33.3% |
Q4 2015 | $6,625,000 | +42.9% | 293,900 | +5.2% | 0.00% | +50.0% |
Q3 2015 | $4,635,000 | -17.4% | 279,400 | +12.1% | 0.00% | -33.3% |
Q2 2015 | $5,609,000 | -12.7% | 249,300 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $6,427,000 | +18.5% | 249,300 | 0.0% | 0.00% | +50.0% |
Q4 2014 | $5,425,000 | +15.0% | 249,300 | 0.0% | 0.00% | 0.0% |
Q3 2014 | $4,719,000 | -21.5% | 249,300 | -3.3% | 0.00% | -33.3% |
Q2 2014 | $6,009,000 | -24.6% | 257,900 | +8.9% | 0.00% | -25.0% |
Q1 2014 | $7,968,000 | +14.0% | 236,800 | 0.0% | 0.00% | +33.3% |
Q4 2013 | $6,990,000 | +108.8% | 236,800 | +8.3% | 0.00% | +50.0% |
Q3 2013 | $3,347,000 | – | 218,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 4,042,989 | $8,571,000 | 0.75% |
NEXTHERA CAPITAL LP | 634,715 | $1,346,000 | 0.26% |
Endurant Capital Management LP | 219,114 | $465,000 | 0.21% |
Birchview Capital, LP | 118,689 | $252,000 | 0.16% |
Perceptive Advisors | 2,620,897 | $5,556,000 | 0.15% |
Alambic Investment Management, L.P. | 53,972 | $114,000 | 0.09% |
Sofinnova Investments, Inc. | 395,744 | $839,000 | 0.08% |
Kazazian Asset Management, LLC | 31,475 | $67,000 | 0.06% |
Broadfin Capital, LLC | 200,000 | $424,000 | 0.06% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 96,639 | $205,000 | 0.02% |